|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
Datamonitor, May 2004, Pages: 90
Fueled by the growing interest in neuropathic pain but keen to avoid competition with larger players, small companies recognize the commercial opportunity of the HIV-related neuropathic pain (HIVNP) market.
Not only does HIVNP offer a well-served patient base and good awareness, it is also a useful stepping-stone to larger more prevalent neuropathic pain types and thus greater commercial gains.
Scope of Report:
Quantitative treatment data from over 171 physicians from the US, France, Germany, Italy, and the UK
Analysis of epidemiology, assessment and referral patterns, first- to third-line treatments, and unmet market needs
Discussion of the R&D drug pipeline for HIVNP, with analysis of NeurogesX’s patch analgesic NGX-4010 and Savient’s nerve growth stimulator Prosaptide
Coverage of the hot topics including education of HIV specialists, reducing pill burden, and the potential of pathogenesis-based treatments
Report Highlights:
In countries such as the US and the UK there is a strong therapeutic relationship between HIVNP patients and HIV specialists. Although patients tend to be well served and treatment initiated reasonably early, there is still a need to educate HIV physicians on HIVNP management.
The tricyclic antidepressant amitriptyline is a popular treatment of neuropathic pain across the 7 markets, although its side effects are intolerable to many HIVNP patients. The newer serotonin and noradrenaline reuptake inhibitor class of antidepressants, however, appears to offer a cleaner side effect profile with equivalent analgesic ability.
In the long-term, the future HIVNP market will see the launch of pathogenesis-based therapies, such as nerve growth factor agonists. However, while the search for effective neurotrophic compounds that can halt or ideally reverse nerve damage causing HIVNP continues, analgesics will remain an important part of pain management.
Reasons to Purchase:
Forecast product sales by understanding key aspects of HIVNP epidemiology, referral, diagnosis, treatment, and unmet needs
Improve pain product positioning strategies by realizing the commercial advantages offered by the HIVNP niche
Understand how the HIVNP market provides an opening to more profitable neuropathic pain indications in the US
Customers who bought this item also bought
Stakeholder Insight: Neuropathic Low Back Pain - Off-label Revenue Despite Diagnostic Challenge
Stakeholder Insight: Diabetic Neuropathic Pain - Market Success is Not Limited to Pregabalin
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Pain Therapeutics - Drugs, Markets and Companies
Neuropathic Pain Insight - Life Beyond Gabapentin
Competitive Strategies in Pain Management, 2001 Edition
Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment Preferences Across the Seven Major Markets
Stakeholder Opinions: HIV/HCV Co-infection - Whose Niche?
|
|
|
|
